Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience

• Published in: Pathology oncology research Vol. 23; no. 4; pp. 753 - 759
• Main Authors: Lakatos, G, Petranyi, A, Szűcs, A, Nehéz, L, Harsanyi, L, Hegyi, P, Bodoky, G
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01-10-2017; Springer Nature B.V
• Subjects: 5-Fluorouracil; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomedical and Life Sciences; Biomedicine; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Cancer Research; Cancer therapies; Carcinoma, Pancreatic Ductal - drug therapy; Chemotherapy; Chemotherapy, Adjuvant - methods; Data processing; Diarrhea; Disease control; Fatigue; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Granulocyte colony-stimulating factor; Humans; Immunology; Incidence; Irinotecan; Leucovorin - administration & dosage; Leucovorin - adverse effects; Male; Metastases; Metastasis; Middle Aged; Nausea; Neoadjuvant Therapy - methods; Neutropenia; Oncology; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Original Article; Oxaliplatin; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pathology; Prophylaxis; Toxicity; FOLFIRINOX; Pancreatic cancer; Locally advanced
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-016-0176-0

The management of locally advanced pancreatic cancer (LAPC) is a major challenge. Although new drugs are available for the treatment of metastatic disease, the optimal treatment of non-metastatic cases remains controversial. The role of neoadjuvant therapy is still a question of debate in this setting. The aim of the study was to prospectively collect and analyse data on efficacy and safety of a modified FOLFIRINOX regimen in LAPC patients treated in a single institution. Another major objective was to assess the capability of FOLFIRINOX to render primary non-resectable cancer to resectable. No bolus fluorouracil was given and a 20% dose reduction of oxaliplatin and irinotecan was applied. Primary G-CSF prophylaxis was applied to prevent febrile neutropenia. Thirty-two patients (mean age 60.2 years, range: 40–77 years) have been enrolled into the study. All patients had ECOG performance status of 0 or 1. Best response to therapy was stable disease (SD) or partial regression (PR) in 18 (56.2%) and 6 (18.8%) cases. Two patients (6.3%) underwent surgical resection (100% R0). The most frequent grade 3/4 adverse events were nausea (18.8%), fatigue (12.5%) and diarrhea (12.5%). The incidence of severe neutropenia was 28.1%, with only one documented case of febrile neutropenia. The probability of disease progression was 25% and 50% after 75 and 160 days with 88.4% of possibility of disease progression after 500 days. OS probability was 92.1, 71.5% and 49.5% at 180-, 365 and 540 days. Our data does not support the capability of FOLFIRINOX to render primary non-resectable cancer to resectable. However, due to the high disease control rate observed, FOLFRINOX might be recommended as first line option for the palliative treatment of LAPC. Despite reduced chemotherapy doses significant toxicity has been seen.